TY - JOUR
T1 - A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro
AU - Vaclavkova, P.
AU - Cao, Y.
AU - Wu, L. K.
AU - Michalek, J.
AU - Vitetta, Ellen S.
N1 - Funding Information:
Correspondence: Dr ES Vitetta, Cancer Immunobiology Center, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA. E-mail: Ellen.Vitetta@UTSouthwestern.edu This work was supported by a grant from Lymphoma and Leukemia Society and by the Cancer Immunobiology Center. 1These authors contributed equally to this work. 2Studies were carried out in partial fulfillment of a doctoral degree in immunology Received 16 September 2005; revised 28 October 2005; accepted 6 December 2005; published online 30 January 2006
PY - 2006/3
Y1 - 2006/3
N2 - Ex vivo depletion of alloreactive CD25+ T cells from a stem cell transplant (SCT) can reduce the incidence of graft-versus-host disease (GVHD) while preserving antimicrobial and perhaps antileukemia activity. However, the most effective methods for allodepleting T cells prior to transplant have not been determined. In this study, we have compared three agents that deplete CD25+ activated, alloreactive T cells. These included Ontak (Denileukin Diftitox), an IL-2 fusion toxin, anti-CD25 microbeads (MACS), an anti-CD25 immunotoxin (IT) and a combination of the IT and MACS. Peripheral blood mononuclear cells (PBMCs) activated in a primary mixed lymphocyte reaction (MLR) were allodepleted using optimal amounts of each agent, and the cells were then analyzed by flow cytometry. The treated cells were examined both for remaining alloreactivity and for the preservation of third party reactivity by testing them in a secondary MLR. Our data demonstrate that both the anti-CD25 IT and the anti-CD25 MACS were equally effective in depleting CD4+CD25+ cells and in sparing T cells that were reactive with third party cells. The anti-CD25 IT was, however, superior in depleting alloreactive CD8+CD25+ cells. In contrast, Ontak did not eliminate alloreactive cells and the Ontak-treated cells retained significant reactivity against the original stimulator cells.
AB - Ex vivo depletion of alloreactive CD25+ T cells from a stem cell transplant (SCT) can reduce the incidence of graft-versus-host disease (GVHD) while preserving antimicrobial and perhaps antileukemia activity. However, the most effective methods for allodepleting T cells prior to transplant have not been determined. In this study, we have compared three agents that deplete CD25+ activated, alloreactive T cells. These included Ontak (Denileukin Diftitox), an IL-2 fusion toxin, anti-CD25 microbeads (MACS), an anti-CD25 immunotoxin (IT) and a combination of the IT and MACS. Peripheral blood mononuclear cells (PBMCs) activated in a primary mixed lymphocyte reaction (MLR) were allodepleted using optimal amounts of each agent, and the cells were then analyzed by flow cytometry. The treated cells were examined both for remaining alloreactivity and for the preservation of third party reactivity by testing them in a secondary MLR. Our data demonstrate that both the anti-CD25 IT and the anti-CD25 MACS were equally effective in depleting CD4+CD25+ cells and in sparing T cells that were reactive with third party cells. The anti-CD25 IT was, however, superior in depleting alloreactive CD8+CD25+ cells. In contrast, Ontak did not eliminate alloreactive cells and the Ontak-treated cells retained significant reactivity against the original stimulator cells.
KW - Alloreactive T cells
KW - Anti-CD25 immunotoxin
KW - Graft-versus-host disease
KW - Magnetic cell sorting
KW - Ontak
KW - Selective depletion
UR - http://www.scopus.com/inward/record.url?scp=33644891348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644891348&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705286
DO - 10.1038/sj.bmt.1705286
M3 - Article
C2 - 16444279
AN - SCOPUS:33644891348
SN - 0268-3369
VL - 37
SP - 559
EP - 567
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -